Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis

Pediatric Research

Volumn 75, Issue 3, 2014, Pages 381-388

  Kum, Jina J Y ^a   Khan, Zia A ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; PROPRANOLOL;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMANGIOMA; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; APOPTOSIS; CASPASE 3; CELL COUNT; CELL PROLIFERATION; CYCLIN D1; HEMANGIOMA; HUMANS; INFANT; MULTIPOTENT STEM CELLS; PROPRANOLOL; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84896812501     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2013.231     Document Type: Article

References (35)

1. Mulliken, J.B. & Glowacki, J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast. Reconstr. Surg. 69, 412-422 (1982).
2. Krol, A. & MacArthur, C.J. Congenital hemangiomas: rapidly involuting and noninvoluting congenital hemangiomas. Arch. Facial Plast. Surg. 7, 307-311 (2005).
3. Kleiman, A., Keats, E.C., Chan, N.G. & Khan, Z.A. Evolution of hemangioma endothelium. Exp. Mol. Pathol. 93, 264-272 (2012).
4. Frieden, I.J., Eichenfield, L.F., Esterly, N.B., Geronemus, R. & Mallory, S.B. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J. Am. Acad. Dermatol. 37, 631-637 (1997).
5. Durr, M.L., Meyer, A.K., Huoh, K.C., Frieden, I.J. & Rosbe, K.W. Airway hemangiomas in PHACE syndrome. Laryngoscope 122, 2323-2329 (2012).
6. Léauté-Labrèze, C., Dumas de la Roque, E., Hubiche, T., Boralevi, F., Thambo, J.B. & Taïeb, A. Propranolol for severe hemangiomas of infancy. N. Engl. J. Med. 358, 2649-2651 (2008).
7. Price, C.J. et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch. Dermatol. 147, 1371-1376 (2011).
8. Richter, G.T. & Friedman, A.B. Hemangiomas and vascular malformations: current theory and management. Int. J. Pediatr. 2012, 645678 (2012).
9. Lamy, S., Lachambre, M.P., Lord-Dufour, S. & Béliveau, R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul. Pharmacol. 53, 200-208 (2010).
10. Bingham, M.M., Saltzman, B., Vo, N.J. & Perkins, J.A. Propranolol reduces infantile hemangioma volume and vessel density. Otolaryngol. Head. Neck Surg. 147, 338-344 (2012).
11. Hogeling, M., Adams, S. & Wargon, O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 128, e259-e266 (2011).
12. Stiles, J. et al. Propranolol treatment of infantile hemangioma endothelial cells: a molecular analysis. Exp. Ther. Med. 4, 594-604 (2012).
13. Ji, Y., Li, K., Xiao, X., Zheng, S., Xu, T. & Chen, S. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. J. Pediatr. Surg. 47, 2216-2223 (2012).
14. Porter, A.G. & Jänicke, R.U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6, 99-104 (1999).
15. Xiao, Q., Li, Q., Zhang, B. & Yu, W. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr. Surg. Int. 29, 575-581 (2013).
16. Georgountzou, A., Karavitakis, E., Klimentopoulou, A., Xaidara, A. & Kakourou, T. Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. Acta Paediatr. 101, e469-e474 (2012).
17. Bagazgoitia, L., Hernández-Martín, A. & Torrelo, A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr. Dermatol. 28, 658-662 (2011).
18. Khan, Z.A. et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J. Clin. Invest. 118, 2592-2599 (2008).
19. Ji, Y., Chen, S., Li, K., Xiao, X., Zheng, S. & Xu, T. The role of ß-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Cell Div. 8, 1 (2013).
20. Stacey, D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell Biol. 15, 158-163 (2003).
21. Wong, A., Hardy, K.L., Kitajewski, A.M., Shawber, C.J., Kitajewski, J.K. & Wu, J.K. Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. Plast. Reconstr. Surg. 130, 1012-1021 (2012).
22. Kermer, P., Klöcker, N., Labes, M. & Bähr, M. Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 In vivo. J. Neurosci. 20, 2-8 (2000).
23. Shimoke, K. & Chiba, H. Nerve growth factor prevents 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. J. Neurosci. Res. 63, 402-409 (2001).
24. Barber, A.J. et al. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J. Biol. Chem. 276, 32814-32821 (2001).
25. Mohan, S. et al. Involvement of NF-κB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone A. Phytomedicine 19, 1007-1015 (2012).
26. Kim, H.R. et al. FGF-2 inhibits TNF-a mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells. BMB Rep. 45, 287-292 (2012).
27. Basile, J.R., Eichten, A., Zacny, V. & Münger, K. NF-kappaB-mediated induction of p21(Cip1/Waf1) by tumor necrosis factor alpha induces growth arrest and cytoprotection in normal human keratinocytes. Mol. Cancer Res. 1, 262-270 (2003).
28. Cheng, K. et al. Antiproliferative effect of tumor necrosis factor-alpha on human glioblastoma cells linked with cell cycle arrest in G1 phase. Neurol. Med. Chir. (Tokyo) 34, 274-278 (1994).
29. Hattori, T., Hayashi, H., Chiba, T. & Onozaki, K. Activation of two distinct anti-proliferative pathways, apoptosis and p38 MAP kinase-dependent cell cycle arrest, by tumor necrosis factor in human melanoma cell line A375. Eur. Cytokine Netw. 12, 244-252 (2001).
30. Communal, C., Singh, K., Sawyer, D.B. & Colucci, W.S. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100, 2210-2212 (1999).
31. Panjala, S.R., Jiang, Y., Kern, T.S., Thomas, S.A. & Steinle, J.J. Increased tumor necrosis factor-a, cleaved caspase 3 levels and insulin receptor substrate- 1 phosphorylation in the ß1-adrenergic receptor knockout mouse. Mol. Vis. 17, 1822-1828 (2011).
32. Steinle, J.J., Booz, G.W., Meininger, C.J., Day, J.N. & Granger, H.J. Beta 3-adrenergic receptors regulate retinal endothelial cell migration and proliferation. J. Biol. Chem. 278, 20681-20686 (2003).
33. Keats, E. & Khan, Z.A. Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose. PLoS ONE 7, e38752 (2012).
34. Kleiman, A., Keats, E.C., Chan, N.G. & Khan, Z.A. Elevated IGF2 prevents leptin induction and terminal adipocyte differentiation in hemangioma stem cells. Exp. Mol. Pathol. 94, 126-136 (2013).
35. Roach, E.E. et al. Intrinsic regulation of hemangioma involution by platelet-derived growth factor. Cell Death Dis. 3, e328 (2012).